Biopharma Here to Stay: The Long-Term Case for the PBE ETF
Biopharma Here to Stay: The Long-Term Case for the PBE ETF PBE tracks the Dynamic Biotech & Genome Intellidex Index, which “is designed to provide capital appreciation by thoroughly evaluating companies based on a variety of investment merit criteria, including price momentum, earnings momentum, quality, management action, and value,” according to Invesco. Due to the high priority of rolling out COVID-19 treatments, some PBE components could enjoy top line growth this year and in 2022. “As with most viruses, developing COVID-19 treatments has been difficult, but several drugs have shown...